Latest Disease-modifying antirheumatic drug Stories
-33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort- MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc.
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in
New research shows mortality rates are two times higher in postmenopausal women with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies.
Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.